CTR20262102 Botulinum Toxin Type A (AsiFlyer) Glabellar frown lines Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Turn a newly registered trial into a decision-ready clinical landscape. This report examines CTR20262102 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.

MCP evidence snapshot: 23 July 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.

Why CTR20262102 is a hot trial to watch

Glabellar frown lines is being segmented by mechanism, treatment setting, geography and endpoint architecture. CTR20262102 is notable because it evaluates Botulinum Toxin Type A (AsiFlyer) in a Phase 2 design sponsored by Shanghai AsiFlyer Biotechnology Co., Ltd.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.

Trial landscape snapshot

Protocol design and endpoint interpretation

The indexed record describes a Phase 2 study of Botulinum Toxin Type A (AsiFlyer) in Glabellar frown lines.

Allocation is 随机化, masking is 双盲, and the intervention model is 平行分组. Planned enrollment of [object Object] participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.

• Primary endpoint (整个研究期间) — （第一阶段）研究期间的不良事件、严重不良事件的发生率；注射部位反应发生率；
• Primary endpoint (整个研究期间) — （第一阶段）研究期间的实验室检查（包括血常规、血生化、尿常规等）、12导联心电图、生命体征、体格检查等有临床意义的异常变化的发生率。
• Primary endpoint (治疗后第28天) — （第二阶段）不同剂量注射用重组A型肉毒毒素（Sf9细胞，150 kD天然氨基酸序列）治疗后第4周研究者和试验参与者对最大皱眉时眉间纹严重程度的现场评估得到的眉间纹改善的复合应答率。

Readout outlook and evidence gap

The current protocol points to Not reported as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.

Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset MCP profile: Botulinum Toxin Type A (AsiFlyer) is indexed as No normalized modality returned, with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status No normalized global status returned.

Company & Deal Intelligence MCP profile: Shanghai AsiFlyer Biotechnology Co., Ltd. is resolved to a normalized organization record in Suzhou, China. The organization workflow adds identity, location, portfolio and partnering context where available.

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
• Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.

Bottom line

CTR20262102 provides a focused lens on Glabellar frown lines development. Its value will be determined by whether Botulinum Toxin Type A (AsiFlyer) can convert the current Phase 2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.